Browse studies

Find your next paid study

1,513 recruiting studies matching your filters

A Phase IIb, Randomized, Assessor-Masked, Multicenter Clinical Trial to Assess the Safety and Efficacy of Subretinal Implantation of the CPCB-RPE1 Implant in Subjects With Advanced, Dry Age-Related Macular Degeneration (Geographic Atrophy) - PATCH AMD

This is a Phase IIb randomized, clinical trial designed to assess the safety and efficacy of unilateral implantation of the CPCB-RPE1 implant in subjects with …

Estimated

~$10 – $8,750

Regenerative Patch Technologies, LLCNCT06557460

A Multi-Center Registry Study to Assess the Safety and Effectiveness of Photobiomodulation (PBM) in Participants With Dry Age-Related Macular Degeneration (AMD) (GLOBALIGHT)

The purpose of this registry study is to collect real life data pertaining to the safety and clinical effectiveness of multi-wavelength photobiomodulation (PBM…

Dry Age-related Macular Degeneration

Estimated

~$10 – $1,050

LumiThera, Inc.NCT06351605

Phase 4

REMIfentanil (2 vs. 4 mcg/kg) Facilitated Intubation Without Neuromuscular Blockade Versus Succinylcholine and Rocuronium With Sugammadex for Endotracheal Intubation in Spine Surgery Requiring Motor Evoked Potential Monitoring

The purpose of this research is to compare four commonly used anesthesia medication strategies for placing a breathing tube in patients undergoing spine surger…

Airway ManagementEndotracheal Intubation

Estimated

~$10 – $6,250

Mayo ClinicNCT07835295

Continuous Assessment of Cerebral Autoregulation in Subarachnoid Hemorrhage (SAH) Patients Using Cerebral Oximetry Index and Hemoglobin Volume Reactivity Index

The goal of this observational study is to continuously assess cerebral autoregulation in patients with subarachnoid hemorrhage (SAH) using cerebral oximetry i…

Subarachnoid Hemorrhage, Aneurysmal

Estimated

~$10 – $750

University of Alabama at BirminghamNCT06932640

Phase 1

Phase I/II Study of the MEK Inhibitor Selumetinib Plus DS-8201a (Trastuzumab Deruxtecan) in KRAS-Mutant, HER2-Expressing Pancreatic Ductal Adenocarcinoma

This phase I/II trial tests the safety, side effects, best dose and how well giving selumetinib with trastuzumab deruxtecan (DS-8201a) works for the treatment …

Advanced Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaStage III Pancreatic Cancer AJCC v8+2 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT07619521

Phase 2

Phase II Pilot Study of Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

This research study aims to determine what effects (good and bad) Durvalumab has on participants and their cancer with a "quick start" of Durvalumab within 14 …

Nonsmall Cell Lung Cancer Stage IIIUnresectable Non-Small Cell Lung CarcinomaNonsmall Cell Lung Cancer, Stage II

Estimated

~$10 – $6,250

Wake Forest University Health SciencesNCT05696782

Phase 1

A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors, Including Checkpoint Inhibitor Naïve Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors

The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well E…

Advanced Solid TumorsMSI-H or dMMR Advanced Solid TumorsMSI-H/dMMR Gastric Cancer+4 more

Estimated

~$10 – $8,750

Eikon TherapeuticsNCT07262619

Phase 1

A Phase 1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand Therapy, in Adults With GRPR-Positive Advanced Solid Tumors (OMNIRAY)

The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination …

Breast NeoplasmsColorectal NeoplasmsProstate Neoplasm+4 more

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07114601

Phase 1

A Phase 1b/2 Open-label Study to Assess the Safety and Efficacy of ASP546C in Participants With CLDN18.2-expressing Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma, Pancreatic Adenocarcinoma or Other Solid Tumor Types

This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other…

Gastric or Gastro-esophageal Junction (GEJ) AdenocarcinomaPancreatic Adenocarcinoma

Estimated

~$10 – $8,750

Astellas Pharma Global Development, Inc.NCT07488676

Phase 1

Phase 1/1b Study of AKT Inhibitor Ipatasertib With Chemoradiation for Locally Advanced Head and Neck Cancer

This phase I/Ib trial tests the safety and best dose of ipatasertib in combination with the usual treatment approach using chemotherapy together with radiation…

Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Head and Neck Carcinoma of Unknown Primary+24 more

Phase 1

A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy With LY4337713 in Adults With FAP-Positive Solid Tumors (FiREBOLT)

This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a p…

Ovarian NeoplasmsBreast NeoplasmsPancreatic Intraductal Neoplasms+4 more

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07213791

Observational

Feasibility Evaluation of a Strap-Based Wearable Optical Device (Hemorai Vysio) for Monitoring Hemodynamic Trends and Early Indicators of Blood Loss in Perioperative and Postoperative Patients

The goal of this clinical trial is to learn whether the Hemorai Vysio wearable device can be used safely and feasibly to track relative changes over time in ti…

Blood Loss, SurgicalPostoperative Hemorrhage

Estimated

~$10 – $8,750

Hemorai IncNCT07826637